Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes to worsening metabolic health and an increased risk of type 2 diabetes.

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

For adults with type 2 diabetes and obesity, GLP-1 RAs are associated with a lower risk for dementia, stroke, and all-cause mortality.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

New research from investigators at Mass General Brigham suggests that a commonly used type 2 diabetes medication is linked to ...

The analysis found that while the amount of weight regain varies by drug, there is a consistent pattern of rapid weight ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Curious about the viral “Japanese Mounjaro” drink? Learn what it is, what it’s made of, and whether it can actually support ...

A new study has found that a diabetes medicine called tirzepatide can help people lower their blood sugar and lose weight ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...